A recent study indicates that patients who stop using popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Published data in a major medical journal points out that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users purchasing these treatments must be aware of the danger of quick rebound weight gain when the treatment ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a return to original weight within about one and a half years.
Comparing Therapies
The analysis, which examined 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
The team note that people who shed pounds through lifestyle changes alone typically see a slower creep back—approximately 100 grams monthly—once they finish.
Explaining the Quick Regain
Doctors propose the mechanism of the injections accounts for the accelerated rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural hormone, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' means hunger is no longer kept in check, making overeating much more probable."
An Ongoing Issue?
The NHS suggest the injections for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, due to the likelihood of weight regain, the therapy should be considered life-long.
This opinion is echoed by drug manufacturers, who say that the findings "emphasize the long-term nature of excess weight," akin to managing diseases like diabetes.
Patient Testimonies
People who have discontinued the jabs explain a intense resurgence of cravings.
"It was like a trigger that goes on and I was suddenly starving," described a patient.
This challenge is compounded if users have not established sustainable lifestyle or habit changes during treatment.
Widespread Adoption
Figures show that millions of adults in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Use is higher among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Finally, experts emphasize that while these medications are effective tools for shedding pounds, they are not a standalone solution and maintained weight loss relies on integrated behavioural management.
